KLOW Blend Peptide – User Manual & Dosage Protocol Guide

1

Product Overview

KLOW Blend Peptide is a proprietary peptide formulation designed to support skin hydration, anti-aging, and cellular rejuvenation. It is commonly used experimentally to:

  • Promote skin elasticity and firmness
  • Reduce the appearance of fine lines and wrinkles
  • Support collagen and elastin synthesis
  • Enhance cellular repair and regeneration

Disclaimer: KLOW Blend Peptide is for research and experimental use only. It is not FDA-approved for cosmetic or medical purposes. Consult a qualified healthcare professional before use.

2

Forms Available

Lyophilized Powder

  • Freeze-dried peptide blend for reconstitution

Injection Solution

  • Subcutaneous (SC) or intramuscular (IM) solution after reconstitution

Oral/Topical (if included)

  • Daily administration; bioavailability may be limited
3

Mechanism of Action

KLOW Blend Peptide contains a synergistic mixture of peptides that may:

  • Stimulate collagen and elastin production in skin tissue
  • Promote cellular repair and regeneration
  • Improve skin hydration, texture, and tone
  • Provide antioxidant and anti-aging support

Effects are primarily observed in research settings and limited human trials.

4

Dosage Protocol (Investigational)

Administration

Subcutaneous (SC) Injection

  • Typical Dose: 2–5 mg
  • Frequency: 2–3× per week
  • Notes: Inject near target areas for localized effect

Intramuscular (IM) Injection

  • Typical Dose: 2–5 mg
  • Frequency: 1–2× per week
  • Notes: Systemic or local injection possible

Oral/Topical (if included)

  • Typical Dose: 250–500 mg
  • Frequency: Daily
  • Notes: Slower effect due to digestion and absorption
Cycle Protocol (Investigational)

Initial Phase

  • Duration: 2–4 weeks
  • Dose: 2 mg SC/IM, 2× per week
  • Notes: Assess tolerance and initial response

Therapeutic Phase

  • Duration: 4–8 weeks
  • Dose: 3–5 mg SC/IM, 2–3× per week
  • Notes: Optimal effect on skin rejuvenation

Rest Period

  • Duration: 1–2 months
  • Dose: None
  • Notes: Allows skin and tissue to reset before the next cycle

Total cycles per year typically range from 2–4 cycles, depending on research goals.

5

Reconstitution Instructions (Lyophilized Powder)

Supplies Needed:

  • Sterile bacteriostatic water
  • Sterile syringe
  • Alcohol swabs

Steps:

  1. Clean vial top with alcohol swab.
  2. Add the desired volume of bacteriostatic water (e.g., 10 mg peptide + 2 mL water → 5 mg/mL solution).
  3. Swirl gently to dissolve; do not shake.
  4. Store reconstituted solution refrigerated (2–8°C).

Use within 2–4 weeks; discard if cloudy or discolored.

6

Administration Guidelines

Subcutaneous Injection (SC)
  1. Select clean injection site near areas of concern (face, neck, arms).
  2. Clean site with alcohol swab.
  3. Insert needle at 45° angle.
  4. Inject slowly; apply gentle pressure afterward.
  5. Rotate injection sites to avoid tissue irritation.
Intramuscular Injection (IM)
  1. Select clean muscle site (deltoid, glute, thigh).
  2. Clean site with alcohol swab.
  3. Insert needle at 90° angle and inject slowly.
  4. Apply gentle pressure afterward.

Tip: SC injections near skin-targeted areas may provide more visible results.

7

Storage Guidelines

Storage Information

Lyophilized Powder

  • Storage: Cool, dry place
  • Shelf Life: Up to 12 months

Reconstituted Solution

  • Storage: Refrigerate at 2–8°C
  • Shelf Life: 2–4 weeks

Oral/Topical

  • Storage: Room temperature, dry place
  • Shelf Life: 12 months

Important:
Discard the solution if it becomes cloudy, discolored, or contains particulates.

8

Safety & Precautions

  • Not for pregnant or breastfeeding women
  • Avoid if allergic to peptides
  • Mild side effects may include irritation at injection site or redness
  • Discontinue if severe adverse reactions occur
  • Keep out of reach of children

Effects in humans are primarily investigational.

9

Quick Reference Cycle Chart (Investigational)

Weekly Cycle Schedule

Week 1–2

  • Dose: 2 mg SC/IM, 2× per week
  • Notes: Initial tolerance phase

Week 3–4

  • Dose: 3 mg SC/IM, 2–3× per week
  • Notes: Therapeutic dose escalation

Week 5–8

  • Dose: 5 mg SC/IM, 2–3× per week
  • Notes: Full therapeutic cycle

Week 9+

  • Dose: Rest
  • Notes: 1–2 month break before the next cycle
10

Visual Guide

  • Diagrams of SC and IM injection sites (facial, neck, arm, thigh, deltoid)
  • Step-by-step reconstitution guide
  • Safety icons for handling, storage, and injections